Department of Pathology, Universidade de Sao Paulo, 01246903 São Paulo, Brasil.
Hum Pathol. 2012 May;43(5):675-83. doi: 10.1016/j.humpath.2011.06.010. Epub 2011 Oct 10.
Heterogeneity of hyaluronidase (HYAL) expression has been identified in tumors and shows promise as an indicator of disease progression. The expression profile of alternatively spliced forms of HYAL was evaluated in tumors and normal lung tissue from 69 resected tumors of patients with adenocarcinomas and squamous cell carcinomas. HYAL1-wild-type (wt) and variants 1 to 5, HYAL2-wt, and HYAL3-wt, and variants 1 to 3 were identified by polymerase chain reaction and direct sequencing. Different proportions of the 3 HYAL-wt and variants were expressed in tumor and normal lung tissues. HYAL1-wt was associated with a poorer prognosis and HYAL3-v1 with a better prognosis. HYAL splice variants are associated with histology and outcome, suggesting that strategies aimed at modulating their levels may be effective for lung cancer treatment.
透明质酸酶 (HYAL) 的表达存在异质性，已被确定为疾病进展的指标。在 69 例腺癌和鳞状细胞癌患者切除肿瘤的肿瘤和正常肺组织中，评估了 HYAL 剪接变体的表达谱。通过聚合酶链反应和直接测序鉴定了 HYAL1-野生型 (wt) 和变体 1 至 5、HYAL2-wt 和 HYAL3-wt 以及变体 1 至 3。在肿瘤和正常肺组织中表达了不同比例的 3 种 HYAL-wt 和变体。HYAL1-wt 与预后较差相关，而 HYAL3-v1 与预后较好相关。HYAL 剪接变体与组织学和结果相关，表明旨在调节其水平的策略可能对肺癌治疗有效。
